z-logo
Premium
Efficacy of topical mesalazine compared with clobetasol propionate in treatment of symptomatic oral lichen planus
Author(s) -
Sardella A,
Demarosi F,
Oltolina A,
Rimondini L,
Carrassi A
Publication year - 1998
Publication title -
oral diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.953
H-Index - 87
eISSN - 1601-0825
pISSN - 1354-523X
DOI - 10.1111/j.1601-0825.1998.tb00289.x
Subject(s) - mesalazine , medicine , clobetasol propionate , oral lichen planus , dermatology , randomized controlled trial , visual analogue scale , gastroenterology , surgery , corticosteroid , ulcerative colitis , disease
OBJECTIVE: To compare topically applied mesalazine (5‐aminosalicylic acid) to topically applied clobetasol propionate in the treatment of patients suffering from symptomatic oral lichen planus. DESIGN: Randomized controlled longitudinal investigation. PATIENTS AND METHODS: Twenty‐five out‐patients suffering from oral lichen planus and referred to the Department of Oral Pathology and Oral Medicine of the University of Milan, Italy, during the period January to August 1997. Patients were randomly allocated (Group A and Group B) to treatment with mesalazine 5% or clobetasol propionate 0.05%. The drugs were topically applied twice daily for 4 weeks. Discomfort and pain were evaluated by the patient before and after treatment using a Visual Analogue Scale from zero (no pain) to 10 (extreme pain). Results were statistically evaluated by a Mann‐Whitney U test. RESULTS: The two pharmacological regimens obtained partial and complete absence of symptoms. In particular, the mesalazine tested group disclosed 57% complete absence of symptoms, 21.3% partial response and 9% no response. No statistically relevant difference has been detected between the two regimens. CONCLUSIONS: The results of this preliminary study, if confirmed by further investigations, suggest that mesalazine might be considered an alternative to clobetasol propionate for treatment of symptomatic oral lichen planus.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here